Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men

Next Previous
X
Search
Trial Profile

An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Cabotegravir (Primary) ; Cabotegravir (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors ViiV Healthcare

    • Most Recent Events

    • 07 Feb 2022 Results published in the Antimicrobial Agents and Chemotherapy
    • 10 Jun 2020 Status changed from active, no longer recruiting to completed.
    • 16 Aug 2018 Planned End Date changed from 7 Mar 2020 to 28 Apr 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top